Abstract:The expanding gene‐editing toolbox has driven a biomedical revolution. These molecular tools tremendously contribute to the progression of fundamental research, such as epigenetics, drug development, disease modeling, and disease diagnosis. Furthermore, therapeutic gene editing offers a profound opportunity to improve the current treatment of human diseases. The expanding genome editing toolbox has revolutionized life science research ranging from the bench to the bedside. These "molecular scissors" have offered us unprecedented abilities to manipulate nucleic acid sequences precisely in living cells from diverse species. Continued advances in genome editing exponentially broaden our knowledge of human genetics, epigenetics, molecular biology, and pathology. Currently, gene editing‐mediated therapies have led to impressive responses in patients with hematological diseases, including sickle cell disease and thalassemia. With the discovery of more efficient, precise and sophisticated gene‐editing tools, more therapeutic gene‐editing approaches will enter the clinic to treat various diseases, such as acquired immunodeficiency sydrome (AIDS), hematologic malignancies, and even severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. These initial successes have spurred the further innovation and development of gene‐editing technology. In this review, we will introduce the architecture and mechanism of the current gene‐editing tools, including clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR‐associated nuclease‐based tools and other protein‐based DNA targeting systems, and we summarize the meaningful applications of diverse technologies in preclinical studies, focusing on the establishment of disease models and diagnostic techniques. Finally, we provide a comprehensive overview of clinical information using gene‐editing therapeutics for treating various human diseases and emphasize the opportunities and challenges.

Gene editing technology as an approach to the treatment of liver diseases

In vivo liver targeted genome editing as therapeutic approach: progresses and challenges

Gene Therapy for Inherited Liver Disease: To Add or to Edit

Advances in precision gene editing for liver fibrosis: From technology to therapeutic applications

Nanogene editing drug delivery systems in the treatment of liver fibrosis

Gene Therapy: Regulations, Ethics and Its Practicalities in Liver Disease

Genetic modification by overexpression of target gene in mesenchymal stromal cell for treating liver diseases

[Gene Editing Technology and Its Recent Progress in Disease Therapy].

CRISPR/Cas9-related technologies in liver diseases: from feasibility to future diversity

Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects

Novel Therapeutic Modalities For Hepatic Diseases

Liver‐directed gene therapy for inherited metabolic diseases

Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma

Efficient expansion and CRISPR-Cas9-mediated gene correction of patient-derived hepatocytes for treatment of inherited liver diseases

Genome-editing Technologies for Gene and Cell Therapy

Current landscape of gene‐editing technology in biomedicine: Applications, advantages, challenges, and perspectives

Therapeutic liver cell transplantation to treat a genetic liver defect

The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases

Gene Editing Correction of a Urea Cycle Defect in Organoid Stem Cell Derived Hepatocyte-like Cells

Gene therapy and gene editing strategies in inherited blood disorders

Recent Therapeutic Gene Editing Applications to Genetic Disorders